drugset / Trial / NCT04318548
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexsero | Vaccine | — | Intramuscular |
| Subject | Meningococcal MenACWY Conjugate Vaccine | Vaccine | — | Intramuscular |